Compare
Zai Lab Ltd vs Nature's Sunshine Products Inc vs Innoviva, Inc. vs Ardelyx, Inc.
| Latest fiscal year | Zai Lab Ltd ZLAB | Nature's Sunshine Products Inc NATR | Innoviva, Inc. INVA | Ardelyx, Inc. ARDX |
|---|---|---|---|---|
| Year ended | 2025-12-31 | 2025-12-31 | 2025-12-31 | 2025-12-31 |
| Revenue | $457.18M | $480.14M | $411.33M | $407.32M |
| Revenue growth (YoY) | +15.0% | +5.7% | +14.7% | +22.1% |
| Gross margin | 58.3% (computed) | 72.4% | 74.8% | 90.3% (computed) |
| Operating margin | -50.2% | 5.2% | 39.8% | -10.1% |
| Net margin | -38.4% | 4.3% | 65.9% | -15.1% |
| Net income | -$175.54M | $20.45M | $271.17M | -$61.60M |
| EPS (Diluted) | -$0.16 | $1.06 | $3.30 | -$0.26 |
| Operating cash flow | -$150.79M | $35.32M | $196.93M | -$42.48M |
| Free cash flow | -$158.89M | $28.84M | $195.80M | -$43.98M |
| Cash & equivalents | $679.57M | $93.89M | $550.94M | $68.00M |
| Total assets | $1.17B | $261.15M | $1.64B | $501.60M |
| Total liabilities | $456.88M | $99.59M | n/a | $334.65M |
| Shareholders' equity | $715.50M | $161.55M | $1.17B | $166.95M |
| Return on year-end equity | -24.5% | 12.7% | 23.1% | -36.9% |
| Shares outstanding | 1.11B | 17.51M | 74.64M | 244.35M |
Revenue, most recent five fiscal years
| Fiscal year | Zai Lab Ltd | Nature's Sunshine Products Inc | Innoviva, Inc. | Ardelyx, Inc. |
|---|---|---|---|---|
| Latest | $457.18M Ended 2025-12-31 | $480.14M Ended 2025-12-31 | $411.33M Ended 2025-12-31 | $407.32M Ended 2025-12-31 |
| 1 year earlier | $397.61M Ended 2024-12-31 | $454.36M Ended 2024-12-31 | $358.71M Ended 2024-12-31 | $333.62M Ended 2024-12-31 |
| 2 years earlier | $266.72M Ended 2023-12-31 | $445.32M Ended 2023-12-31 | $310.46M Ended 2023-12-31 | $124.46M Ended 2023-12-31 |
| 3 years earlier | $212.67M Ended 2022-12-31 | $421.91M Ended 2022-12-31 | $331.34M Ended 2022-12-31 | $52.16M Ended 2022-12-31 |
| 4 years earlier | $144.10M Ended 2021-12-31 | $444.08M Ended 2021-12-31 | $391.87M Ended 2021-12-31 | $10.10M Ended 2021-12-31 |